Ana Lledo Delgado, MD
Associate Research ScientistCards
About
Research
Publications
2026
Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes
Wu Y, Spurrell M, Lledó-Delgado A, Deng S, Wang D, Liu Y, Barkestani M, Perdigoto A, Herold K. Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes. JCI Insight 2026, 11: e192755. PMID: 41574610, PMCID: PMC12892913, DOI: 10.1172/jci.insight.192755.Peer-Reviewed Original Research
2025
Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
Lledó-Delgado A, Preston-Hurlburt P, Higdon L, Hu A, James E, Lim N, Long S, McNamara J, Nguyen H, Serti E, Sumida T, Herold K. Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes. Nature Communications 2025, 16: 5033. PMID: 40447640, PMCID: PMC12125364, DOI: 10.1038/s41467-025-60276-5.Peer-Reviewed Original Research
2024
Teplizumab induces persistent changes in the antigen‐specific repertoire in individuals at‐risk for type 1 diabetes
Lledó-Delgado A, Currie S, Clark P, Linsley P, Long S, Liu C, Koroleva G, Martins A, Tsang J, Herold K. Teplizumab induces persistent changes in the antigen‐specific repertoire in individuals at‐risk for type 1 diabetes. Journal Of Clinical Investigation 2024, 134: e177492. PMID: 39137044, PMCID: PMC11405034, DOI: 10.1172/jci177492.Peer-Reviewed Original Research
2022
Shorter telomere length is associated with COVID-19 hospitalization and with persistence of radiographic lung abnormalities
Retuerto M, Lledó A, Fernandez-Varas B, Guerrero-López R, Usategui A, Lalueza A, García-García R, Mancebo E, Paz-Artal E, Sastre L, Perona R, Pablos J. Shorter telomere length is associated with COVID-19 hospitalization and with persistence of radiographic lung abnormalities. Immunity & Ageing 2022, 19: 38. PMID: 35996190, PMCID: PMC9394033, DOI: 10.1186/s12979-022-00294-9.Peer-Reviewed Original Research
2021
SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy
Lledó A, Retuerto M, Almendro-Vázquez P, Fernández-Ruiz M, Galindo M, Laguna-Goya R, Paz-Artal E, Lalueza A, Aguado J, Pablos J. SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy. Seminars In Arthritis And Rheumatism 2021, 51: 1258-1262. PMID: 34775160, PMCID: PMC8572149, DOI: 10.1016/j.semarthrit.2021.10.006.Peer-Reviewed Original Research
2020
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, Fernandez-Fernandez D, Fernandez-Gutierrez B, Galindo-Izquierdo M, Gonzalez-Gay MA, Manrique-Arija S, Mena Vázquez N, Mera Varela A, Retuerto M, Seijas-Lopez A, RIER investigators group.. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis 2020, 79: 1170-1173. PMID: 32532753, DOI: 10.1136/annrheumdis-2020-217763.Peer-Reviewed Original ResearchClinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
Pablos J, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay M, Martinez-Lopez D, Castrejón I, Alvaro-Gracia J, Fernández D, Mera-Varela A, Manrique-Arija S, Vázquez N, Fernandez-Nebro A, group R, Aguirre R, Seijas-López Á, Blanco F, Carreira P, Martín-López M, Gonzalez A, Puig-Kröger A, Salas L. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Annals Of The Rheumatic Diseases 2020, 79: 1544-1549. PMID: 32796045, DOI: 10.1136/annrheumdis-2020-218296.Peer-Reviewed Original ResearchAdenosine MonophosphateAge FactorsAgedAlanineAntiviral AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusCardiovascular DiseasesCase-Control StudiesCohort StudiesComorbidityConnective Tissue DiseasesCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug CombinationsFemaleGlucocorticoidsHospitalizationHumansHydroxychloroquineImmunosuppressive AgentsLogistic ModelsLopinavirLupus Erythematosus, SystemicMaleMiddle AgedObesityPandemicsPneumonia, ViralPolymyalgia RheumaticaPrognosisRheumatic DiseasesRisk FactorsRitonavirSARS-CoV-2Severity of Illness IndexSex FactorsSjogren's SyndromeSpondylarthropathies